FTFranck Touret

Franck Touret

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Franck Touret has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Hugo Roux

    Aix-Marseille Université, CNRS, ICR UMR 7273, PCR, Faculté de Pharmacie, 13005, Marseille, France

    1 shared publication
  • Manon Roche

    AP-HM, Service Central des Opérations Pharmaceutiques (SCOP), France

    1 shared publication
  • Pascal Rathelot

    Service Central de la Qualité et de l’Information Pharmaceutiques (SCQIP), Pharmacy Department, Assistance Publique-Hôpitaux de Marseille, 174 Boulevard Baille, 13005 Marseille, France

    1 shared publication
  • Patrice Vanelle

    CNRS, ICR UMR 7273, Team Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Aix Marseille University, 27 Boulevard Jean Moulin, CS30064, CEDEX 05, 13385 Marseille, France

    1 shared publication

Latest Publications

  • Open Access

    From the “One Molecule – One Target – One Disease” Concept towards Looking for Multi-target Therapeutics for Treating Non-polio Enterovirus (Npev) Infections

    by Hugo Roux, Franck Touret, Pascal Rathelot, Patrice Vanelle, Manon Roche

    Non-polio enteroviruses (NPEVs), namely coxsackieviruses (CV), echoviruses (E), enteroviruses (EV), and rhinoviruses (RV), are responsible for a wide variety of illnesses. Some infections can progress to life-threatening complications in children or immunocompromised patients. To date, no treatments have been approved. Several molecules have been evaluated through clinical trials without success. To overcome these failures, the multi-target directed ligand (MTDL) strategy can be applied to tackle enterovirus infections. This work analyzes clinical trials to highlight the best candidates and develops filters to apply to a selection for MTDL synthesis. We explicitly stated the methods used to answer the question: Which solution can fight NPEVs effectively? We note the originality and relevance of this proposal in relation to the state of the art in the enterovirus-inhibitors field. Several combinations are possible to broaden the antiviral spectrum and potency. We discuss data related to the virus and data related to each LEAD compound identified. Overall, this study proposes a perspective on different strategies to overcome issues identified in clinical trials and evaluate the “MTDL” potential to improve the efficiency of drugs synergistically, broaden the targeted, and reduce the adverse effects and drug design cost as well as limit the opportunity of drug-resistant viruses.